Department of Gastroenterology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Department of Traditional Chinese Medicine, Second Military Medical University/Naval Medical University, Shanghai, China.
Clin Transl Oncol. 2023 Feb;25(2):535-554. doi: 10.1007/s12094-022-02968-8. Epub 2022 Oct 18.
PURPOSE: The main function of cartilage oligomeric matrix protein (COMP) is to maintain the synthesis and stability of the extracellular matrix by interacting with collagen. At present, there are relatively few studies on the role of this protein in tumors. This study aimed to explore the relationship between COMP and pan-cancer, and analyzed its diagnostic and prognostic value. METHODS: The Cancer Genome Atlas database, the Genotype-Tissue Expression database and the Cancer Cell Line Encyclopedia database was used for gene expression analysis. The receiver operating characteristic curve was used to assess the diagnostic value of COMP in pan-cancer. Kaplan-Meier plots were used to assess the relationship between COMP expression and prognosis of cancers. R software v4.1.1 was used for statistical analysis, and the ggplot2 package was used for visualization. RESULTS: COMP was significantly overexpressed in 15 human cancers and showed significantly difference in 12 molecular subtypes and 16 immune subtypes. In addition, the expression of COMP is associated with tumor immune evasion. The ROC curve showed that the expression of COMP could predict the occurrence of 16 kinds of tumors with relative accuracy, including adrenocortical carcinoma (ACC) (AUC = 0.737), breast invasive carcinoma (BRCA) (AUC = 0.896), colon adenocarcinoma (COAD) (AUC = 0.760), colon adenocarcinoma/rectum adenocarcinoma esophageal carcinoma (COADREAD) (AUC = 0.775), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC) (AUC = 0.875), kidney renal papillary cell carcinoma (KIRP) (AUC = 0.773), kidney chromophobe (KICH) (AUC = 0.809), ovarian serous cystadenocarcinoma (OV) (AUC = 0.906), prostate adenocarcinoma (PRAD) (AUC = 0.721), pancreatic adenocarcinoma (PAAD) (AUC = 0.944), rectum adenocarcinoma (READ) (AUC = 0.792), skin cutaneous melanoma (SKCM) (AUC = 0.746), stomach adenocarcinoma (STAD) (AUC = 0.711), testicular germ cell tumors (TGCT) (AUC = 0.823), thymoma (THYM) (AUC = 0.777) and uterine carcinosarcoma (UCS) (AUC = 0.769). Furthermore, COMP expression was correlated with overall survival (OS), disease-specific survival (DSS) and progression-free interval (PFI) in ACC (OS, HR = 4.95, DSS, HR = 5.55, PFI, HR = 2.79), BLCA (OS, HR = 1.59, DSS, HR = 1.72, PFI, HR = 1.36), KIRC (OS, HR = 1.36, DSS, HR = 1.94, PFI, HR = 1.57) and COADREAD (OS, HR = 1.46, DSS, HR = 1.98, PFI, HR = 1.43). We selected previously unreported bladder urothelial carcinoma (BLCA) for further study and found that COMP could be an independent risk factor for OS, DSS and PFI. Moreover, we found differentially expressed genes of COMP in BLCA and obtained top 10 hub genes, including LGR4, LGR5, RSPO2, RSPO1, RSPO3, RNF43, ZNRF3, FYN, LYN and SYK. Finally, we verified the function of COMP at the cellular level by using J82 and T24 cells and found that knockdown of COMP could significantly inhibit migration and invasion. This finding supports that COMP could be a potential biomarker for pan-cancer diagnosis and prognosis encompassing tumor microenvironment, disease stage and prognosis. CONCLUSION: This finding supports that COMP could be a potential biomarker for pan-cancer diagnosis and prognosis encompassing tumor microenvironment, disease stage and prognosis.
目的:软骨寡聚基质蛋白(COMP)的主要功能是通过与胶原蛋白相互作用来维持细胞外基质的合成和稳定性。目前,关于这种蛋白质在肿瘤中的作用的研究相对较少。本研究旨在探讨 COMP 与泛癌的关系,并分析其诊断和预后价值。
方法:使用癌症基因组图谱数据库、基因组织表达数据库和癌症细胞系百科全书数据库进行基因表达分析。使用受试者工作特征曲线评估 COMP 在泛癌中的诊断价值。通过 Kaplan-Meier 图评估 COMP 表达与癌症预后的关系。使用 R 软件 v4.1.1 进行统计分析,并使用 ggplot2 包进行可视化。
结果:COMP 在 15 种人类癌症中显著过表达,在 12 种分子亚型和 16 种免疫亚型中存在显著差异。此外,COMP 的表达与肿瘤免疫逃逸有关。ROC 曲线显示,COMP 的表达可以相对准确地预测 16 种肿瘤的发生,包括肾上腺皮质癌(ACC)(AUC=0.737)、乳腺浸润性癌(BRCA)(AUC=0.896)、结肠腺癌(COAD)(AUC=0.760)、结肠腺癌/直肠腺癌食管癌(COADREAD)(AUC=0.775)、淋巴样肿瘤弥漫性大 B 细胞淋巴瘤(DLBC)(AUC=0.875)、肾肾乳头细胞癌(KIRP)(AUC=0.773)、肾嫌色细胞癌(KICH)(AUC=0.809)、卵巢浆液性囊腺癌(OV)(AUC=0.906)、前列腺腺癌(PRAD)(AUC=0.721)、胰腺腺癌(PAAD)(AUC=0.944)、直肠腺癌(READ)(AUC=0.792)、皮肤黑色素瘤(SKCM)(AUC=0.746)、胃腺癌(STAD)(AUC=0.711)、睾丸生殖细胞肿瘤(TGCT)(AUC=0.823)、胸腺瘤(THYM)(AUC=0.777)和子宫癌肉瘤(UCS)(AUC=0.769)。此外,COMP 表达与 ACC 的总生存期(OS)(HR=4.95)、疾病特异性生存期(DSS)(HR=5.55)和无进展间隔(PFI)(HR=2.79)、BLCA 的 OS(HR=1.59)、DSS(HR=1.72)和 PFI(HR=1.36)、KIRC 的 OS(HR=1.36)、DSS(HR=1.94)和 PFI(HR=1.57)和 COADREAD 的 OS(HR=1.46)、DSS(HR=1.98)和 PFI(HR=1.43)有关。我们选择了之前未报道的膀胱癌进行进一步研究,发现 COMP 可以作为 OS、DSS 和 PFI 的独立危险因素。此外,我们发现了 BLCA 中 COMP 的差异表达基因,并获得了前 10 个枢纽基因,包括 LGR4、LGR5、RSPO2、RSPO1、RSPO3、RNF43、ZNRF3、FYN、LYN 和 SYK。最后,我们使用 J82 和 T24 细胞在细胞水平上验证了 COMP 的功能,发现下调 COMP 可以显著抑制迁移和侵袭。这一发现支持 COMP 可能是一种潜在的泛癌诊断和预后生物标志物,涵盖肿瘤微环境、疾病阶段和预后。
结论:这一发现支持 COMP 可能是一种潜在的泛癌诊断和预后生物标志物,涵盖肿瘤微环境、疾病阶段和预后。
Clin Transl Oncol. 2023-2
Comput Struct Biotechnol J. 2022-6-18
Comput Struct Biotechnol J. 2022-6-24
Comput Struct Biotechnol J. 2020-3-19
Comput Struct Biotechnol J. 2021-8-14
Comput Struct Biotechnol J. 2022-1-7
Int J Mol Sci. 2024-5-30